Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BBNX
Upturn stock ratingUpturn stock rating

Beta Bionics, Inc. Common Stock (BBNX)

Upturn stock ratingUpturn stock rating
$16.71
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: BBNX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

Analysis of Past Performance

Type Stock
Historic Profit -0.73%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 945.12M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -
52 Weeks Range 8.89 - 24.50
Updated Date 06/22/2025
52 Weeks Range 8.89 - 24.50
Updated Date 06/22/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.3

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -104.64%
Operating Margin (TTM) -65.71%

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 891525977
Price to Sales(TTM) 17.82
Enterprise Value 891525977
Price to Sales(TTM) 17.82
Enterprise Value to Revenue 16.81
Enterprise Value to EBITDA -
Shares Outstanding 43334300
Shares Floating 41336549
Shares Outstanding 43334300
Shares Floating 41336549
Percent Insiders 6.74
Percent Institutions 55.22

ai summary icon Upturn AI SWOT

Beta Bionics, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Beta Bionics is a private company focused on developing and commercializing innovative technologies for diabetes management. Founded to address unmet needs in automated insulin delivery, it evolved from research conducted at Boston University.

business area logo Core Business Areas

  • Automated Insulin Delivery: Develops and commercializes automated insulin delivery (AID) systems, also known as artificial pancreas systems, for people with diabetes.

leadership logo Leadership and Structure

Sean Saint is the CEO of Beta Bionics. The company's structure revolves around research and development, regulatory affairs, and commercialization of their iLet Bionic Pancreas system.

Top Products and Market Share

overview logo Key Offerings

  • iLet Bionic Pancreas: The iLet Bionic Pancreas system is an AID system that automates insulin dosing decisions. Market share information is proprietary and not publicly disclosed as it is a private company. Competitors include Medtronic (MDT), Insulet (PODD), and Tandem Diabetes Care (TNDM).

Market Dynamics

industry overview logo Industry Overview

The diabetes management industry is experiencing growth driven by technological advancements in AID systems, continuous glucose monitoring (CGM), and connected devices. The industry is competitive with established players and emerging innovators.

Positioning

Beta Bionics is positioned as an innovator in AID technology with the iLet Bionic Pancreas, aiming to improve glycemic control and reduce the burden of diabetes management for users. Their competitive advantage lies in their bionic pancreas technology.

Total Addressable Market (TAM)

The global diabetes management market is projected to reach hundreds of billions of dollars. Beta Bionics is targeting a portion of this TAM focused on automated insulin delivery systems.

Upturn SWOT Analysis

Strengths

  • Innovative bionic pancreas technology
  • Focus on automated insulin delivery
  • Strong scientific foundation

Weaknesses

  • Limited financial resources as a private company
  • Dependence on a single product
  • Relatively smaller market presence compared to larger competitors

Opportunities

  • Expanding market for AID systems
  • Partnerships with healthcare providers and insurers
  • Potential for international expansion

Threats

  • Competition from established medical device companies
  • Regulatory hurdles and reimbursement challenges
  • Technological obsolescence

Competitors and Market Share

competitor logo Key Competitors

  • MDT
  • PODD
  • TNDM

Competitive Landscape

Beta Bionics faces strong competition from established players like Medtronic, Insulet, and Tandem Diabetes Care. Its competitive advantage lies in its innovative technology, but it needs to scale up to compete effectively.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data is not publicly available for Beta Bionics.

Future Projections: Future growth projections are dependent on successful commercialization and adoption of the iLet Bionic Pancreas system.

Recent Initiatives: Recent initiatives include securing regulatory approvals for their products and expanding their commercial infrastructure.

Summary

Beta Bionics is an innovative company with its bionic pancreas system which makes their product cutting edge. They have a competitive landscape against established players in the market, where scaling to meet demands and commercialization will be vital for growth. Securing partnerships, reimbursement, and regulatory approvals are all key factors. The lack of financial disclosure due to its private status makes it hard to get a precise idea how well they are doing as a company.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company press releases
  • Industry reports
  • Analyst estimates

Disclaimers:

This analysis is based on publicly available information and analyst estimates. Actual performance may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Beta Bionics, Inc. Common Stock

Exchange NASDAQ
Headquaters Irvine, CA, United States
IPO Launch date 2025-01-30
President, CEO & Director Mr. Sean T. Saint PE
Sector Healthcare
Industry Medical Devices
Full time employees 352
Full time employees 352

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.